- Home
- COEP vs SCYX Comparison
COEP vs SCYX Comparison
Compare COEP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- SCYX
- Stock Information
- Founded
- COEP 2017
- SCYX 1999
- Country
- COEP United States
- SCYX United States
- Employees
- COEP N/A
- SCYX N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- SCYX Health Care
- Exchange
- COEP Nasdaq
- SCYX Nasdaq
- Market Cap
- COEP 27.4M
- SCYX 28.5M
- IPO Year
- COEP N/A
- SCYX 2014
- Fundamental
- Price
- COEP $9.84
- SCYX $0.82
- Analyst Decision
- COEP
- SCYX
- Analyst Count
- COEP 0
- SCYX 0
- Target Price
- COEP N/A
- SCYX N/A
- AVG Volume (30 Days)
- COEP 37.4K
- SCYX 176.2K
- Earning Date
- COEP 08-15-2025
- SCYX 08-07-2025
- Dividend Yield
- COEP N/A
- SCYX N/A
- EPS Growth
- COEP N/A
- SCYX N/A
- EPS
- COEP N/A
- SCYX N/A
- Revenue
- COEP $62,874.00
- SCYX $2,630,000.00
- Revenue This Year
- COEP N/A
- SCYX $463.61
- Revenue Next Year
- COEP N/A
- SCYX $310.80
- P/E Ratio
- COEP N/A
- SCYX N/A
- Revenue Growth
- COEP N/A
- SCYX N/A
- 52 Week Low
- COEP $2.31
- SCYX $0.66
- 52 Week High
- COEP $13.70
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- COEP 62.24
- SCYX 57.87
- Support Level
- COEP $7.25
- SCYX $0.67
- Resistance Level
- COEP $9.90
- SCYX $0.75
- Average True Range (ATR)
- COEP 0.63
- SCYX 0.04
- MACD
- COEP 0.26
- SCYX 0.01
- Stochastic Oscillator
- COEP 85.62
- SCYX 93.53
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.